Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT06140537
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Diabetes
- Kidney Transplant; Complications
- Vascular Diseases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin 10mg Tab — DRUGDapagliflozin 10mg orally daily
- Placebo — DRUGPlacebo one tablet orally daily
Study Details
Long-term allograft function in kidney transplant recipients (KTRs) remain suboptimal, and graft failure causes significant morbidity and mortality, with cardiovascular disease being the leading cause of death in KTRs and the most common cause of death with a functioning graft. Sodium-glucose cotransporter 2 (SGLT2) inhibitors safely lower cardiovascular and kidney disease risk in the non-transplant population, yet data in KTRs are lacking. This clinical trial seeks to establish the efficacy and safety of dapagliflozin, a SGLT2 inhibitor, for improving cardiovascular and kidney graft function in adult KTRs with type 2 diabetes and post-transplant diabetes, and to leverage innovate translational methods to define the underlying mechanisms of action.
Key Dates
- Start date
- Feb 1, 2024
- Status verified
- May 2025
- Primary completion
- Oct 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DapagliflozinParticipants will receive dapagliflozin 10mg daily
- Placebo Comparator: PlaceboParticipants will receive one placebo tablet daily
Primary Outcome Measure
Albuminuria [ Time Frame: Change from baseline to 12 months ]
Central Contacts
- Jessica Kendrick3037244837
- Petter Bjornstad
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Rachael Reddin |
Find similar trials in Aurora, CO
Related Studies
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntolerancePHASE2 · Recruiting · University of Pennsylvania · Aurora, Colorado
- Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant RecipientsPHASE4 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- The Diabetes Prevention Program Outcomes Study AD/ADRD ProjectEnrolling By Invitation · Marinella Temprosa · Phoenix, Arizona